01Follow activation into a measurable signal

Lonza’s official recombinant factor C assay documentation describes an endotoxin-activated enzyme acting on a fluorogenic substrate. The resulting fluorescence is measured against endotoxin standards.Lonza — PyroGene recombinant factor C assay documentation (opens in a new tab)

This is an enzyme-response assay, not sequencing of a bacterium or direct weighing of lipopolysaccharide. Its result remains an activity measurement interpreted through the defined reaction and calibration.

A fluorescence signal must still be attributable to the intended reaction. Background fluorescence or changes in enzyme performance are analytical questions to investigate through controls, not reasons to accept or reject an entire method family.

02Distinguish recombinant factor C from recombinant cascades

USP’s chapter <86> includes both recombinant factor C and recombinant cascade approaches. Its official announcement states that the chapter became official in May 2025 and adds techniques alongside those in <85>; it does not require existing LAL users to abandon their methods.USP — Approval of recombinant endotoxin-test chapter (opens in a new tab)

A recombinant cascade uses more than the single factor C detection component. “Recombinant” therefore identifies a broader reagent category and does not by itself specify one reaction architecture or readout.

FDA’s March 2026 announcement explains that its revised endotoxin guidance accommodates a broader range of recombinant reagents. This updates older discussions that described recombinant testing as simply awaiting recognition.FDA — Current thinking on pyrogen and endotoxin testing (opens in a new tab)

Recognition of a method is separate from approval of a particular product, laboratory or report. It also does not supply the missing sample-specific verification record. Avoid using a chapter number as a general quality endorsement.

03Look for matrix-specific performance evidence

Kang and colleagues evaluated recombinant factor C testing using reference endotoxin and biopharmaceutical samples. They examined analytical performance and found that some samples produced greater interference with the recombinant assay than with the compared LAL assays; suitable dilution addressed the observed interference in their study.Kang and colleagues — Recombinant factor C testing of biopharmaceuticals (opens in a new tab)

That result supports evaluation in the actual matrix. It does not establish that dilution always resolves every problem or that the same dilution is suitable for a different peptide material.

If a laboratory switches methods, compare the same sample basis and relevant concentration range. A comparison confined to large standard spikes may leave uncertainty about performance near the limit that matters for the material.

04Keep the reported conclusion attached to its method

For an original comparison, imagine a recombinant assay reports below 0.05 EU/mL and another method reports 0.03 EU/mL, both on the original-sample basis. Those statements can be compatible; the bounded result does not claim a measured zero.

A meaningful disagreement requires more than different printed formats. Compare uncertainty, reporting limits, calibration and matrix controls before selecting one number as the true value.

The result remains an endotoxin result. It does not establish absence of viable organisms or all non-endotoxin pyrogens, and it does not demonstrate that a research material is suitable for human use.